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An earlier report from the Tuberculosis Chemotherapy Centre, Madras, showed that,
in tuberculous patients receiving high-dosage isoniazid (12.5-15.6 mg/kg body-weight),
the concomitant administration of 6 mg of pyridoxine prevented peripheral neuropathy.
In that study, biochemical determinations of B6 concentrations and GOT activity in whole
blood had been routinely undertaken on all patients on admission to treatment, and at 6,
12, 24 and 52 weeks thereafter; in addition, extra determinations were undertaken for
patients who developed peripheral neuropathy. The present paper reports the findings of
these investigations, which are: (a) peripheral neuropathy developed predominantly among
slow inactivators of isoniazid, and was associated with a substantial reduction in GOT
activity but no apparent change in B6 concentration; (b) the reduction in GOT activity
appeared to be due to deficiency of both the coenzyme (pyridoxal phosphate) and the
apoenzyme; (c) the concomitant administration of pyridoxine (6 mg or 48 mg) with
high-dosage isoniazid to 3 patients with peripheral neuropathy, 1 of whom had convulsions
also, resulted in increased B6 concentrations and GOT activity, and no further convulsions;
and(d) the concomitant administration of pyridoxine 6 mg daily, as a prophylactic, resulted
in a significant increase in B6 concentrations and GOT activity and prevention of the
neuropathy.
These findings establish the existence of a definite association between the occurrence
of isoniazid-induced toxicity and diminished pyridoxine function.
Peripheral neuropathy, a well-known complication cil Isoniazid Investigation, 1960) and in the treatment
of isoniazid therapy in tuberculosis, is now recognized of the complication (Oestreicher, Dressler & Middle-
to be related to a state of pyridoxine deficiency; thus, brook, 1954; Tchertkoff et al., 1956; Devadatta et
pyridoxine has been used successfully both in the al., 1960). Increased excretion of vitamin B6 in
prophylaxis (Biehl & Vilter, 1954; Tchertkoff et al., urine (Biehl & Vilter, 1954; Short, 1962) and
1956; East African/British Medical Research Coun- reduction in whole-blood glutamic-oxaloacetic trans-
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aminase (GOT; aspartate-aminotransferase 1) acti-
vity-an enzyme requiring vitamin B6 in the form of
pyridoxal phosphate as the cofactor-have also been
observed in patients receiving high-dosage isoniazid
(Sass & Murphy, 1958; Bonstein et al., 1961), lending
support to this view.
In a double-blind study undertaken in 1961 at this
Centre, the prophylactic effect of 4 vitamin supple-
ments on the frequency of peripheral neuropathy was
assessed in 98 patients with pulmonary tuberculosis
(Tuberculosis Chemotherapy Centre, 1963). All the
patients were treated with a single daily dose of 12%
15.6 mg of isoniazid per kg body-weight, and were
allocated at random to one of four vitamin supple-
ments, administered daily-namely, (a) a vitamin-B-
complex preparation containing aneurine hydro-
chloride, riboflavine, nicotinamide, panthenol, and
cyanocobalamin, but no pyridoxine, (b) the above
preparation plus 6 mg of pyridoxine, (c) 6 mg of
pyridoxine, or (d) 48 mg of pyridoxine. It was
found that peripheral neuropathy occurred in 7
of 24 patients who received the B-complex pre-
paration without the pyridoxine, as compared with
none of 74 who received 6 mg or more of pyridoxine.
This paper presents the findings of biochemical
investigations undertaken during the course of the
above study to obtain information on the following
aspects: (1) whether. administration of isoniazid in
a high dosage leads to a reduction in vitamin B6
concentration and GOT activity in whole blood;
(2) if so, whether the reduction is greater in patients
developing peripheral neuropathy than in others;
(3) whether reduction in GOT activity is due to
depletion of the coenzyme (pyridoxal phosphate)
and/or the apoenzyme; and (4) whether clinical
observations regarding the prophylactic effect of
pyridoxine are supported by the laboratory
investigations.
METHODS
The criteria for admission of patients to the study,
the bacteriological, clinical and neurological investi-
gations undertaken prior to admission and during
the year of treatment, the details of management
including assessments of regularity in drug-taking,
have all been reported in detail earlier (Tuberculosis
Chemotherapy Centre, Madras, 1963). The great
majority of patients belonged to the poorest section
1 Terminology recommended by the Commission on
Enzymes of the International Union of Biochemistry (Florkin
& Stotz, 1965).
of the population, and came from the same areas in
the city of Madras as in earlier studies. In this com-
munity, it has previously been shown that the nutri-
tional status, including the intake of B-group
vitamins, is subnormal (Ramakrishnan et al., 1961,
1966); however, no patient in the present study had
clinical evidence of neurological abnormalities on
admission.
Chemotherapy and supplements
Isoniazid in a high dosage of 12.5-15.6 mg/kg
body-weight (mean dosage 14.0 mg/kg body-weight)
was given as a single daily dose for 1 year to 98 pa-
tients who were allocated at random to 1 of 4 vitamin
supplement series-namely:
(a) Pyridoxine-free series (24 patients). Three
tablets twice daily, each tablet containing 10 mg of
aneurine hydrochloride, 5 mg of riboflavine, 50 mg
of nicotinamide, 3 mg of panthenol and 1 µg cyano-
cobalamin; in addition, an “ overage ” of 10%
riboflavine, 10 % panthenol, 33 % aneurine hydro-
chloride and 50% cyanocobalamin had been added
by the manufacturers.
(b) B-complex series (24 patients). Three tablets
twice daily, each tablet containing all the vitamins in
the same amounts (including overages) as in the
above preparation plus 1 mg of pyridoxine with an
overage of not more than 10%.
(c) Pyridoxine-6 series (26 patients). Three
tablets twice daily, each tablet containing 1 mg of
pyridoxine plus an overage of not more than 10%.
(d) Pyridoxine-48 series (24 patients). Three
tablets twice daily, each tablet containing 8 mg of
pyridoxine plus an overage of not more than 10%.
Method of dispensing isoniazid and supplements
The morning dose, consisting of isoniazid plus
supplement, was dispensed in a pink paper envelope,
and the evening dose, consisting of supplement only,
in a white paper envelope. The patients received a
7-day supply of envelopes at each weekly visit to the
Centre. Since the B-complex and pyridoxine-free
tablets softened in the humid conditions of Madras,
both the morning and the evening doses of these sup-
plements were heat-sealed in small polyethylene
bags before being placed in their envelopes.
General management
A surprise visit was paid twice weekly by a health
visitor to the patients’ homes to check the regularity
of drug-taking by counting the stock of envelopes
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and by collecting a specimen of urine for testing for
isoniazid by the combined naphthoquinone-mercuric-
chloride test (Gangadharam et al., 1958). As a
further check on regularity, a specimen of urine was
also collected from the patients at each weekly
routine attendance at the Centre.
Diagnosis of peripheral neuropathy, its management
and treatment
The procedures adopted for diagnosing peri-
 pheral neuropathy and assessing its progress have
been reported in detail previously (Tuberculosis
Chemotherapy Centre, Madras, 1963). In brief,
when two of the Centre’s physicians agreed that one
or more physical signs of neuropathy were present,
the patient was examined by an independent
assessor (Dr S. Janaki, Dr K. V. Mathai or Dr G.
M. Taori of the Christian Medical College, Vellore).
If the assessor confirmed the diagnosis, the patient’s
supplement was changed to 48 mg of panthenol
(given in two doses) but the isoniazid was continued.
If, despite the change, the neuropathy (which
occurred only in the pyridoxine-free series) was
regarded as having advanced by two of the Centre’s
physicians, panthenol was stopped and pyridoxine
was given in a daily dosage of 6 mg (in two doses);
the high dosage of isoniazid was, however, continued.
Rate of inactivation of isoniazid
On admission to the study, the rate of inactivation
of isoniazid was determined for each patient by the
procedure of Gangadharam et al. (1961).
Biochemical determinations
Total vitamin B6 concentrations and GOT activity
were determined in the whole blood of patients on
admission to the study and at 6, 12, 24, 36 and
52 weeks during the course of treatment. For
patients who developed peripheral neuropathy,
additional determinations were made soon after
 diagnosis by the independent assessor but before
the change of supplement, and also just prior to
each subsequent change of supplement. All the
determinations were done “ blind ”, that is, the
laboratory was not aware of the nature of the
supplement given to any patient or of the nature of
any subsequent changes.
Collection of blood samples
Blood samples were usually collected from 1 to
4 hours after the patients had taken their morning
dose of isoniazid plus supplement. No special
efforts were made either to ensure that the patients
had taken their morning dose or to regulate the time
elapsing between the ingestion of the tablets and the
collection of the blood sample. However, for the
36-week estimations, the morning dose of isoniazid
and supplement was withheld from the patients until
after their blood samples were collected.
5 ml of blood were collected from each patient by
venepuncture and transferred to a 28-ml Universal
screw-capped bottle containing glass beads and 10 ml
of distilled water. (The actual volume of blood trans-
ferred was recorded if less than 5.0 ml). The bottle
was shaken mechanically to effect haemolysis and
the determinations of vitamin B6 concentration and
GOT activity were made on the haemolysate, as
described below.
Determination of vitamin B6 in blood
The vitamin B6 present in the blood was liberated
from its conjugated form by preliminary acid
hydrolysis according to the procedure of Greenberg
& Rinehart (1949). The resulting filtrate was used
for the determination of vitamin B6 by the micro-
biological procedure using Saccharomyces carls-
bergensis ATCC 4228 as the assay organism, as
recommended by the Association of Vitamin Chem-
ists (1951), but employing standards containing
0.0005 µg, 0.0010 µg, 0.0015 µg . . . 0.0040 µg of
pyridoxine hydrochloride per 10 ml. The growth
was estimated by taking turbidimetric readings, and
the total B6 concentration expressed as micrograms
of pyridoxine hydrochloride in 100 ml of blood.
The assay measures pyridoxine, pyridoxal, pyri-
doxamine and their phosphate esters.
The tests were set up in batches and the B6 con-
centrations in all the blood specimens in a batch
were calculated from the standards set up with that
batch. If the growth of the assay organisms was
heavy, the assay was repeated after suitable dilutions
of the extracts with distilled water. Normally, the
assays were performed on the day the blood samples
were received. However, on some occasions (parti-
cularly at the start of the investigation), the blood
extracts were stored (covered with black paper) in
the refrigerator (at about 4%) for a few days before
the assays were performed.
Determination of GOT activity in whole blood
The whole-blood GOT activity was estimated by
the method described by Yatzidis (1960). The
GOT determinations were made in duplicate for
each sample on the day it was received, and the GOT
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activity for the sample was expressed as micrograms
of pyruvic acid formed per millilitre of blood
per hour. (Determinations of GOT activity made
with haemolysates prepared with less than 4.5 ml of
blood and 10.0 ml of water were considered unsatis-
factory, and have therefore not been included in any
of the analyses.)
Determination of GOT activity with and without the
addition of pyridoxal phosphate (PLP)
Since the above method is not suitable for investi-
gations on the effect of preincubation with PLP
on the GOT activity, the following procedure was
adopted.
Blood haemolysates (0.2 ml) were incubated at
37°C with 0.5 ml of 0.1 M L-aspartate reagent
containing potassium phosphate (pH 7.4) and
20 µg of pyridoxal phosphate in 0.2 ml (where
necessary) for 10 minutes before the reaction was
started by the addition of 0.2 ml of 0.1 M a-keto-
glutarate. Trichloracetic acid (0.2 ml of 50%) was
added to the blanks before the addition of a-keto-
glutarate. The rest of the procedure was as de-
scribed by Tonhazy, White & Umbreit (1950), and
the GOT activity was expressed as micrograms of
pyruvic acid formed per millilitre of blood per hour.
RESULTS
Sex, age and rate of inactivation of isoniazid
Of the 24 patients in the pyridoxine-free series,
75% were males compared with 58 % of 24 in the
B-complex series, 42% of 26 in the pyridoxine-6
series and 54% of 24 in the pyridoxine-48 series.
The proportions of patients aged 35 years or above
were 29%, 33 %, 54% and 46 %, respectively.
The proportions of slow inactivators in the four
series were broadly similar-namely, 67%, 58%,
69% and 67%, respectively.
Vitamin B6 concentrations in blood
The mean B6 concentrations in blood on admission
to treatment and at 6, 12, 24 and 52 weeks after the
start of treatment are presented in Table 1.
On admission to treatment. The B6 concentration
was determined on admission to treatment in only
76 patients; for the remaining 22, which included the
first 18 patients admitted to the study, the deter-
mination could not be made as the blood extract
became contaminated during storage. The mean
values on admission were 0.90 µg/100 ml for the
-
PYRIDOXINE IN SUPPRESSION OF SIDE-EFFECTS OF HIGH-DOSAGE ISONIAZID 857
pyridoxine-free, 1.15 µg/100 ml for the B-complex,
0.96 µg/100 ml for the pyridoxine-6, and 0.97 µg/100
ml for the pyridoxine-48 series; the differences were
all within the usual range of sampling fluctuations
(P> 0.05). Considering all the 76 patients, the “ over-
all pre-treatment mean ” was 1.00 µg/100 ml, and the
range for the middle 95 % of the values (i.e., excluding
2.5% of the values at each extreme)–hereinafter
referred to as the “ 95 % range ” (see the annex)–
was 0.50-1.83 µg/100 ml.
During treatment. Wide variation was observed
in the B6 concentrations during treatment in the
three series receiving a pyridoxine supplement; thus,
the 95% range for all values obtained at 6, 12, 24
and 52 weeks was 0.75-4.66 µg/100 ml in the B-com-
plex series, 0.87-12.50 µg/100 ml in the pyridoxined
series, and 1.87-84.38 µg/100 ml in the pyridoxine-
48 series. In each of these series, the means at 6, 12,
24 and 52 weeks were broadly similar, and hence a
comprehensive mean, based on all the values
obtained at these occasions together with estimates
for missing values (see the annex), was computed
for each series, and is referred to as the “ treatment
mean ”; this mean is evidently the average value of
the treatment means for individual patients. This
was 2.30 µg/100 ml for the B-complex series,
3.54 µg/100 ml for the pyridoxined series, and
25.83 µg/100 ml for the pyridoxine-48 series. In all
three series, the difference between the treatment
mean and the over-all pretreatment mean attained
statistical significance (P<0.001). In the B-complex
and pyridoxine-6 series, in both of which patients
received 6 mg of pyridoxine, the mean increase was
1.30 µg/100 ml and 2.54 µg/100 ml, respectively, the
difference not being statistically significant (P = 0.l-
0.2); in the pyridoxine-48 series, the increase was
significantly larger (P<0.005), being 24.83 µg/100 ml.
Considering the pyridoxine-free series, the mean
 at 6 weeks (1.66 µg/100 ml) was significantly higher
than the over-all pretreatment mean of 1.00 µg/
100 ml (P<0.01). The means at 24 and 52 weeks
were also higher, but these, as well as the mean at
12 weeks, were less than the mean at 6 weeks.
Despite these variations, the treatment mean was
computed for each patient (taking only the estimates
before diagnosis in the case of patients who devel-
oped peripheral neuropathy), and the average value
of these means taken as the treatment mean for the
series. This was 1.24 µg/100 ml, which also was
significantly, higher than the over-all pretreatment
mean (P<0.01).
Rate of inactivation isoniazid. On admission to
treatment, the mean B6 concentration was 0.96 µg/
100 ml for the slow inactivators and 1.07 µg/100 ml
for the rapid inactivators, a non-significant dif-
ference (P ~ 0.2).
Table 2 presents the mean B6 concentrations
during treatment, separately for the slow and the
rapid inactivators of isoniazid in each of the four
series. There was no clear association between the
rate of inactivation of isoniazid and the treatment
mean. In the pyridoxined series, the rapid inac-
tivators had a treatment mean of 5.25 µg/100 ml,
which was appreciably higher than the mean of
2.78 µg/100 ml for the slow inactivators; however,
this difference was not statistically significant
(P>0.2). Moreover, further examination of the
data showed that the high value for the former mean
(which was also much higher than the corresponding
mean in the B-complex series) was due mainly to
4 estimates (12.50 µg/100 ml, 12.50 µg/100 ml,
22.50 µg/100 ml and 29.58 µg/100 ml) that were
substantially higher than those usually observed in
this series; these values were possibly due to the
interval being short between the ingestion of the
supplement and the collection of the blood specimen,
or to self-administration of more than one dose of
the supplement on the morning of the test, or to
both.
TABLE 2
MEAN VITAMIN B6 CONCENTRATIONS
IN BLOOD (µg/100 ml) DURING TREATMENT ACCORDING
TO THE RATE OF INACTIVATION OF ISONIAZID a
Supplement
series
Pyrldoxine-free c
B-complex
Pyridoxine-6
Pyridoxine-46
Rate of inactivation
of isoniazid Treatment mean 
b
Slow 1.16 (16)
Rapid 1.38 (6)
Slow 2.40 (14)
Rapid 2.16 (10)
Slow 2.78 (18)
Rapid 5.25 (8)
Slow 27.67 (16)
Rapid 22.37 (8)
a Figures in parentheses are the numbers of patients on
which the means are based.
b For definition, see text (this page).
c For patients who developed peripheral neuropathy, only
the estimates obtained before diagnosis are included.
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In summary, the mean B6 concentrations on
admission to treatment were similar in the four
series. The treatment mean in each of the four series
(including the pyridoxine-free series) was signifi-
cantly higher than the over-all pretreatment mean,
the difference being largest in the pyridoxine-48
series. There was no association between the B6
concentrations in blood and the rate of inactivation
of isoniazid, either on admission to treatment or
during treatment
GOT activity in whole blood
The mean values of the GOT activity in whole
blood on admission to treatment and at 6, 12, 24
and 52 weeks after the start of treatment are pre-
sented in Table 3.
On admission to treatment. Only 79 patients had
satisfactory pretreatment determinations, the blood
samples being inadequate (less than 4.5 ml) in the
remaining 19. The mean GOT activity was 498 units
in the pyridoxine-free series, 524 units in the B-com-
plex series, 468 units in the pyridoxine-6 series, and
536 units in the pyridoxine-48 series; all the differ-
ences were within the range of usual sampling fluc-
tuations (P>0.05). The over-ail pretreatment mean
for all 79 patients was 504 units, the 95% range
being 3 15-702 units.
During treatment. The 95% range for the GOT
values during treatment was 197-637 units in the
pyridoxine-free series, 388-856 units in the B-com-
plex series, 427-877 units in the pyridoxine-6 series,
and 486-857 units in the pyridoxine-48 series; thus,
the increase in variation during treatment (relative
to that on admission–see above) was less than in
the case of B6 concentrations.
In each of the four series, the mean GOT activities
at 6, 12, 24 and 52 weeks were broadly similar, so
that a treatment mean was computed for each series,
as in the case of B6 estimates. This was 410 units
for the pyridoxine-free series, 620 units for the
B-complex series, 620 units for the pyridoxine-6
series and 695 units for the pyridoxine-48 series.
The treatment mean for the pyridoxine-free series
was significantly lower than the over-all pretreatment
mean of 504 units (P<0.001), the reduction in the
activity being maximal at 12 weeks (27% of the
over-all pretreatment mean); all 7 cases of peri-
pheral neuropathy in this study had occurred in this
series. In contrast, in each of the three series
receiving pyridoxine, the treatment mean was signi-
ficantly higher than the over-all pretreatment mean
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(P<0.001). The increase was identical in the
B-complex and the pyridoxine-6 series-namely,
116 units-as compared with 191 units in the pyri-
doxine-48 series, the difference (75 units) being
statistically significant (P<0.01).
Rate of inactivation of isoniazid. On admission to
treatment, the mean GOT activity was higher for
the rapid inactivators (534 units) than for the slow
inactivators (486 units). However, this difference
 was not significant (P ~ 0.07), and was presumably
due to chance, since, in a subsequent series of 63
rapid and 84 slow inactivators at this Centre, the
finding was reversed, the mean GOT activity being
576 and 613 units, respectively.
The mean GOT activity during treatment is set
out in Table 4, separately for the slow and the rapid
inactivators in each of the four series. Considering
first the pyridoxine-free series, the mean for the slow
inactivators was lower than that for the rapid
inactivators (P = 0.1); it will be appreciated that
the progressive withdrawal during the year of
patients who developed peripheral neuropathy-
these were predominantly slow inactivators and had
reduced GOT activity at the time of withdrawal
(see below)–must have resulted in an over-estimate
of the treatment mean for the slow inactivators, and
consequently an underestimate of the difference in
means between the slow and the rapid inactivators.
The slow inactivators had a lower mean GOT in the
B-complex (P ~ 0.02) and the pyridoxined series
(P = 0.1-0.2) also. The combined probability that
the differences between the slow and the rapid inac-
tivators in these three series were caused by sampling
fluctuations was about 1 in 100 (i.e., P ~ 0.01). In the
pyridoxine-48 series, the difference was reversed,
presumably on account of the large dose of pyri-
doxine.
In summary, the mean GOT activities on admission
were similar in the four series. The treatment mean
in the pyridoxine-free series (all 7 cases of peripheral
neuropathy occurred in this series) was significantly
lower than the pretreatment mean, while in the
remaining three series, a significant elevation was
observed, the maximum increase being in the pyri-
doxine-48 series. There was clear evidence that
the slow inactivators in the pyridoxine-free, B-com-
plex and pyridoxine-6 series had, on the average, a
lower GOT during treatment than the rapid inac-
tivators.
Vitamin B6 concentrations and GOT activity in
patients who developed peripheral neuropathy
Peripheral neuropathy developed in 7 patients in
this study, all in the pyridoxine-free series (Table 5);
it developed more frequently among the slow inac-
tivators, there being 6 cases among 16 slow inac-
TABLE 4
MEAN GOT ACTIVITY a IN WHOLE BLOOD DURING TREATMENT, ACCORDING TO RATE
OF INACTIVATION OF ISONIAZID b
Supp lemen t
series
Pyridoxine-free d
B-complex
Pyridoxine-6
Pyridoxine-46
Rate
of inactivation
of isoniazid
At 6 weeks
Slow 408 (16)
Rapid 469 (8)
At 12 weeks At 24 weeks At 52 weeks Treatment
mean c
349 (14) 402 (11) 418 (10) 369 (16)
402 (8) 419 (8) 492 (6) 436 (8)
538 (14) 558 (13) 608 (14) 588 (14)
633 (10) 650 (10) 721 (10) 665 (10)
593 (18) 562 (16) 651 (16) 609 (18)
647 (8) 631 (8) 631 (8) 646 (8)
722 (16) 694 (16) 709 (14) 706 (16)
665 (8) 666 (8) 721 (8) 674 (8)
a Expressed as µg of pyruvic acid formed per ml of blood per hour under standard assay conditions.
b Figures In parentheses are the numbers of patients on which the means are based.
c For definition, see text (page 667).
d For patients who developed peripheral neuropathy, only the estimates obtained before diagnosis are included.
Serial
number
Rate of
inactivation
of isoniazid
On admission
to treatment
B6 GOT
Last routine test First change of
before diagnosis
At time of change
Supplement
B6 G O T  In te rva l
b B6 GOT Interval 
b
K11 Slow
K75 Slow
K45 Slow
K93 Slow
K71 Rapid
K49 Slow
K57 Slow
– 626 0.62 287 (6) 0.67 385 (8) Panthenol
0.75 715
659
0.92 394 (24) 1.04 177 (42) Panthenol
– 1.25 394 (6) 0.87
c  522 c (9) Panthenol
0.83 451 1.08 264 (12) 0.79 222 (18) Panthenol
0.83 551 2.12 326 (24) 1.54 282 (42) Panthenol
0.62 308 0.79 225 (12) 0.58
d  145d (17) Pyridoxine-48 mg
0.83. 362 0.83 266 (24) 0.75 
e 105e (52) Pyridoxine-6 mg.
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TABLE 5. VITAMIN B6 CONCENTRATIONS (µg/100 ml) AND GOT ACTIVITY 
a IN WHOM
Mean 0.77 525 1.09 308 0.90 219
a Expressed as µg of pyruvic acid formed per ml of blood per hour under standard assay conditions.
b Number of weeks since commencement of treatment.
c These determinations were made one day after the change of supplement to panthenol (results omitted when computing
the means).
tivators in this series compared with 1 among 8
rapid inactivators. For 6 of these 7 cases, in addi-
tion to the routine determinations of B6 concentra-
tion and GOT activity, determinations were made
soon after the diagnosis of the neuropathy but just
prior to the change of supplement. The latter means
were 0.90 µg/100 ml for the B6 concentration and
219 units for the GOT activity, as compared with
pretreatment means of 0.77 µg/100 ml and 525 units,
respectively. The increase in the mean B6 concen-
tration did not attain statistical significance (P = 0.3),
but the reduction in the mean GOT activity was
highly significant (P <0.005). (In the 7th patient,
K45, the determinations “ at the time of change ”
were made one day after the supplement was
changed to panthenol; therefore, although pre-
sented in Table 5, the results have not been included
when computing means.)
It is of interest to compare the B6 concentrations
and the GOT activities at or about the time of
development of the neuropathy in the above
6 patients (i.e., excluding K45) with the values
obtained during treatment from the 17 patients in
the same series (pyridoxine-free) who did not
develop the neuropathy. For the former, the mean
of the B6 estimates obtained just prior to the change
of supplement was 0.90 µg/100 ml as compared with
a treatment mean of 1.25 µg/100 ml for the latter
(P ~ 0.07). Considering the GOT activity, the cor-
responding mean values were 219 units for those
who developed the neuropathy and 427 units for
those who did not, the difference being highly
significant statistically (P<0.0001).
In slow inactivators, the corresponding mean B6
concentrations were 0.77 µg/100 ml for the 5 patients
who developed peripheral neuropathy and 1.20 µg/
100 ml for the 10 who did not, a statistically signi-
ficant difference (P ~ 0.02); the corresponding means
for GOT activity were 207 and 410 units, respec-
tively-again a statistically significant difference
(P ~ 0.001).
In summary, peripheral neuropathy occurred pre-
dominantly among slow inactivators, and was
associated with a substantial reduction in their
whole-blood GOT activity. Patients who developed
this complication had. on the average, a markedly
lower GOT activity and a lower B6 concentration
during treatment as compared with those who did
not develop it.
Of the 7 patients who developed neuropathy,
5 received 48 mg of panthenol daily as the first change
of supplement (Table 5); 4 of these had GOT estima-
tions undertaken after the change to panthenol.
In one of these (K75), there was some subjective
improvement and the GOT increased to 407 units
at 52 weeks. Another (K11) had some progression
of his symptoms, followed by considerable ame-
lioration (the GOT activity increased to 512 units
at 52 weeks), which coincided with extreme irregu-
larity in taking both isoniazid and supplement.
In the remaining 2 patients (K45, K93), there was
progression of the signs and symptoms of the neuro-
pathy which necessitated a further change of sup-
plement to 6 mg of pyridoxine. At the time of
change, their GOT activities had decreased con-
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supplement Second change of supplement
At last routine test
GOT Interval bB6
At time of change
Interval bB6 GOT
Supplement
At last routine test
B6 GOT Interval 
b
2.08 512 (52)
0.83 407 (52)
1.36 310 (12)
0.89 298 (24)
1.25 – (52)
28.2 783 (52)
– – –
–
Pyridoxine-6 mg
Pyridoxine-6 mg
– –
– – –
1.33 969 (52)
2.01 616 (52)
d This patient had convulsions on the day these determinations were made.
e This patient had convulsions on the day these determinations were made: peripheral neuropathy was confirmed by
the independent assessor In the 13th month.
siderably from the values at the preceding routine
test, and were as low as 248 and 214 units, respect-
ively. It may therefore be concluded that the admi-
nistration of panthenol failed to produce a sustained
increase in the GOT activity in at least 2 of the
patients. With the introduction of pyridoxine. the
GOT values increased in these 2 patients to 969
and 616 units, respectively, at 52 weeks, the B6 con-
centration at the time also having increased from
1.02 to 1.33 µg/100 ml in one patient and from 0.88
to 2.01 µg/100 ml in the other; however, both
patients showed little, if any, improvement in symp-
toms and signs.
Two patients, both of whom were slow inactivators
and had developed peripheral neuropathy, also had
convulsions. One of these (K49) developed first
symptoms of neuropathy in the 3rd month and
had 4 convulsions in one week in the 4th month, and
became mentally disorientated. The B6 concentra-
tion at this time was 0.58 µg/100 ml and the GOT
activity was 145 units, as compared with values of
0.62 µg/100 ml and 308 units, respectively, on admis-
sion to treatment. At this stage, the supplement was
changed to 48 mg of pyridoxine daily; he had no
further convulsions and his mental condition
improved. Further, the B6 concentrations increased,
being 3.75 µg/100 ml at 1 week, 4.76 at 2 weeks,
11.9 at 3 weeks and 3.84 at 5 weeks after the change
of supplement to pyridoxine; the GOT activities at
the corresponding periods also showed increases,
being 373, 745, 540 and 532 units, respectively.
Pyridoxine was continued in the same dosage for the
rest of the year, at the end of which the B6 con-
centration was 28.2 µg/100 ml and the GOT activity
783 units. The other patient (K57) had complained
of symptoms of peripheral neuropathy in the 4th
month and had recurring convulsions from the 8th
month onwards. His supplement was not changed
during the year because there was some doubt about
the cause of the convulsions and because the diag-
nosis of peripheral neuropathy was confirmed only
in the 13th month. At 52 weeks, he had convulsions
on the day the blood sample was collected, the Bs
concentration at this time being 0.75 µg/100 ml and
the GOT activity 105 units (the lowest encountered
in this study), as compared with 0.83 µg/100 ml and
362 units, respectively, on admission to treatment.
The disease was bacteriologically quiescent at this
time; the patient was prescribed isoniazid 400 mg
plus pyridoxine 6 mg daily, and had no convulsions
subsequently.
Effect of withholding the morning dose of isoniazid plus
supplement on B6 concentration and GOT activity
When the results of 6- and 12-week determinations
had become available, it was observed that the B6
concentrations in patients receiving pyridoxine, and
in particular in the pyridoxine-48 series, showed
wide variation. This was probably due to the interval
between the ingestion of the morning dose of sup-
plement (plus isoniazid) and collection of the blood
specimen being variable–namely, 1-4 hours (see
page 855). Further, many of these samples would have
contained high concentrations of isoniazid, which is
known to inhibit enzyme systems requiring vitamin
B6 (e.g., Yoneda & Asano, 1953; Davison, 1956;
Meister & Downey, 1956; Jenkins, Orlowski
& Sizer, 1959; Nakada, 1964). In such circumstances,
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the interpretation to be attached to a low GOT is
rather uncertain; thus, it could be due either to the
presence of high concentrations of isoniazid in the
blood samples or to sustained changes in the phy-
siological system resulting from prolonged iso-
niazid therapy. To clarify these issues, B6 and GOT
determinations were undertaken at 36 weeks before
the morning dose of isoniazid plus supplement was
administered-that is, 24 hours after the last
scheduled dose of isoniazid and 12 hours after the
last scheduled dose of supplement. The findings are
presented in Table 6, which also gives the over-all
pretreatment mean and the treatment mean for
each of the four series.
The mean B6 concentration at 36 weeks was
1.04 µg/100 ml in the pyridoxine-free series, a value
which was very similar to the over-all pretreatment
mean of 1.00 µg/100 ml. The mean was slightly
higher both in the B-complex series (1.18) and in the
pyridoxine-6 series (1.13) and markedly higher in
the pyridoxine-48 series (5.28), presumably due to the
dose of the supplement taken the previous evening;
the difference between the mean at 36 weeks and the
over-all pretreatment mean was statistically signi-
ficant in the B-complex and pyridoxine-48 series.
Comparing next the B6 values at 36 weeks with
those obtained during treatment (i.e., at 6, 12, 24,
52 weeks), the mean at 36 weeks was significantly
lower than the corresponding treatment mean in
each of the four series, the difference being 0.20 µg/
100 ml in the pyridoxine-free series (P ~ 0.02),
1.12 µg/100 ml in the B-complex series (P<0.001),
2.41 µg/100 ml in the pyridoxine-6 series (P<0.001),
and 20.55 µg/100 ml in the pyridoxine-48 series
(P<0.001). It is difficult to explain the reason for
the difference in the pyridoxine-free series, but in the
other three series, where the difference was larger,
the finding is not surprising since, at 36 weeks, the
patients had not had any supplement for at least
12 hours before the test, whereas at 6, 12, 24 and
52 weeks they had, in all likelihood, taken a dose
of supplement about 1-4 hours prior to the test.
Considering next the GOT activity, the mean at
36 weeks was about 50 units lower in the pyridoxine-
free series than the pretreatment mean (P=0.1-0.2),
but over 150 units higher in both the B-complex and
the pyridoxine-6 series (P<0.001), and 365 units
higher in the pyridoxine-48 series (P<0.001).
In all four series, the mean at 36 weeks was higher
than the corresponding treatment mean. Thus, the
difference was 42 units in the pyridoxine-free series,
39 units in the B-complex series and 46 units in the
pyridoxine-6 series; none of these was statistically
significant. In contrast, the difference was substantial
(174 units) in the pyridoxine-48 series, and highly
significant (P <0.001). It is possible that the greater
depression of GOT activity at 6, 12, 24 and 52
weeks was due to the presence of high concentra-
tions of isoniazid in the blood, which was collected
probably 1-4 hours after the dose of isoniazid, in
contrast to the low concentrations of isoniazid pre-
sent at 36 weeks when it had been taken at least
TABLE 6
EFFECT OF WITHHOLDING MORNING DOSE OF ISONIAZID PLUS SUPPLEMENT ON MEAN B6
CONCENTRATION (µg/100g ml) AND GOT ACTIVITY a IN WHOLE BLOOD
Estimation
GOT
Supplement series
Pyridoxine-free
B-complex
Pyridoxine-6
Pyridoxine-48
Pyridoxine-free
B-complex
Pyridoxine-6
Pyridoxine-48
C o n t r a s t  b e t w e e n  
(A) and (B)
(B-A)      
1.18 +0.18
1.00
1.13 +0.13
5.28 +4.28
452 - 5 2
659                  +155
504
666 +162
869 +365
P
0.3-0.4
-0.02
0.1-0.2
<0.001
0.1-0.2
<0.001
<0.001
<0.001
Treatment
mean b
(C)
1.24
2.30
3.54
25.83
410
620
620
695
Contrast between
(B) and (C)
(B-C)
-0.20
-1.12
-2.41
-20.55
+42
+39
+46
+174
P
~ 0.022 
<0.001
<0.001
<0.001
0.1-0.2
0.1-0.2
~ 0.06
<0.001
a Expressed as µg of pyruvic acid formed per ml of blood per hour under standard assay conditions.
b For definition, see text (page 857).
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24 hours previously. Further, it is possible that the
large amounts of B6 circulating in the blood (parti-
cularly in the pyridoxine-48 series) soon after the
administration of supplement could be present as
unchanged pyridoxine, an enzymatically inactive
form that could compete with the active structural
analogue, pyridoxal phosphate, for the active sites
on the enzyme molecule, and thus bring about an
inhibition of GOT activity.
To investigate this possibility, experiments in vitro
were undertaken in which large amounts of pyri-
doxine and/or isoniazid were incorporated in the
standard assay system for determining the GOT
activity. These showed that the addition of pyri-
doxine in concentrations equivalent to 75-1503 µg/
100 ml of blood (corresponding to approximately
3-60 times the mean concentrations of B6 attained
during treatment in the pyridoxine48 series) reduced
the GOT activity by only 2%-3%. Similarly, the
addition of isoniazid in concentrations equivalent
to 15-750 µg/ml of blood (corresponding to approxi-
mately 1-50 times the concentration normally
attained in blood on the dosage employed in this
study) reduced the GOT activity only by 6%-8%.
Further, the addition of both pyridoxine and iso-
niazid in concentrations equivalent to 7500 µg/100 ml
and 150 µg/ml of blood respectively brought about
little reduction in the GOT activity. These findings
do not seem to support the explanation given above
for the lower GOT activity observed at 6, 12, 24
and 52 weeks compared with that at 36 weeks;
however, since experiments in vitro do not always
represent conditions as they exist in the physio-
logical system, the possibility cannot be excluded
that the reduced GOT activity observed was due to
the high concentrations of the metabolic products
of isoniazid and pyridoxine circulating in the
blood.
Effect of preincubation with pyridoxal phosphate on
the GOT activity
It was stated earlier that, during treatment with
isoniazid, there was a significant reduction in GOT
activity in the pyridoxine-free series. As GOT is
an enzyme containing pyridoxal phosphate (PLP)
as the coenzyme, and as it is known that isoniazid
greatly increases the excretion of vitamin B6, prob-
ably by the formation of pyridoxal isonicotinoyl
hydrazone, it is likely that the reduction in the GOT
activity was due to an insufficiency of pyridoxal
phosphate. Further, the increase in mean GOT
activity during treatment was significantly larger in
the pyridoxine-48 series than in the B-complex and
the pyridoxined series, suggesting that 6 mg of
pyridoxine a day were not sufficient to bring about
the maximum elevation in the GOT activity. This
insufficiency might partly be due to the fact that
isoniazid is a powerful inhibitor of pyridoxal kinase,
an enzyme catalysing the conversion of pyridoxine
and pyridoxal to their respective phosphates
(McCormick & Snell, 1959). In order to explore
these possibilities, the effect of preincubation of
blood with PLP was studied in samples obtained at
52 weeks from 32 patients receiving the high dosage
of isoniazid; these patients were selected at random,
there being 7 in the pyridoxine-free series, 9 in the
B-complex series and 8 each in the pyridoxine-6 and
the pyridoxine-48 series. The determinations were
made following the procedure described on page 856
and the findings are presented in Table 7.
TABLE 7
EFFECT OF PREINCUBATION WITH PYRIDOXAL PHOSPHATE (PLP) ON THE GOT ACTIVITY a IN WHOLE BLOOD
Supplement
series
Mean GOT Mean GOT
Number activity without
Change due to preincubation with PLP
of patients addition
activity with
addition Treatment
of PLP of PLP Mean Standard
(Y -X ) error of mean
Percentage mean 
b
(X) (Y)
increase
Pyridoxine-free 7 225 438 213 21 95 410
B-complex  9 536 677 141 36 26 620
Pyridoxine-6 8 532 660 128 40 24 620
Pyridoxine-43 8 566 680 114 41 20 695
a Expressed as µg of pyruvic acid formed per ml of blood per hour under standard assay conditions.
b Based on all patients in the series; for definition of treatment mean, see text (page357). The figures in this column are not
directly comparable with those in the rest of the table since the latter estimations were undertaken employing a different method
bee page 355).
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Considering the mean GOT activities without
PLP, they show the same pattern as the treatment
means in the last column; thus, the mean GOT
activity in the pyridoxine-free series was substantially
lower than those in the other three series. Pre-
incubation with an excess of PLP resulted in an
increase of GOT activity in all the four series; the
increase was in the region of 20 %-25 % in the three
series receiving a pyridoxine supplement and as
much as 95 % in the pyridoxine-free series. Even after
preincubation with PLP, the mean GOT activity in
the pyridoxine-free series was considerably lower
than that in the other three series without the pre-
incubation with PLP; this suggests that there might
have been a depletion of the apoenzyme also in the
pyridoxine-free series. In contrast, the differences
between the B-complex series and the pyridoxined
series on the one hand and the pyridoxine-48 series
on the other became smaller after preincubation
with PLP, which suggests that the insufficiency of
the 6 mg of pyridoxine referred to above is due to
the inhibitory effect of isoniazid on pyridoxal kinase.
DISCUSSION
Isoniazid toxicity is generally confined to dis-
turbances in the nervous system, the most common
manifestations being peripheral neuropathy and
convulsions. There is abundant evidence to suggest
that these are due to pyridoxine deficiency. Thus,
while pyridoxine alone in a dosage as small as 6 mg
completely suppressed the development of the neuro-
pathy and probably prevented convulsions, a vitamin
preparation containing aneurine hydrochloride, ribo-
flavine, nicotinamide, panthenol and cyanocoba-
lamin (but no pyridoxine) failed to do so (Tubercu-
losis Chemotherapy Centre, Madras, 1963). Further,
 pyridoxine, in much higher dosages, has previously
been used successfully in the prevention and treat-
ment of the neuropathy (Biehl & Vilter, 1954;
Oestreicher, Dressler & Middlebrook, 1954; Tchert-
koff et al., 1956; Devadatta et al., 1960; East African/
British Medical Research Council Isoniazid Inves-
tigation, 1960).
The metabolic antagonism between isoniazid and
pyridoxine is illustrated by the fact that several
enzyme systems of microbial and mammalian origin
which require pyridoxal phosphate are inhibited
by isoniazid, both in vitro and in vivo (e.g., Yoneda,
Kato & Okajima, 1952; Davison, 1956; Meister &
Downey, 1956; Braunstein, 1957; Jenkins, Orlowski
& Sizer, 1959; Nakada, 1964). In the present study,
this antagonism has been investigated by serial
determinations of vitamin B6 concentrations and
GOT activity in whole blood of 98 patients treated
at home for one year with high-dosage isoniazid
(12.5-15.6 mg/kg body-weight; i.e., 650 mg for a
patient weighing 100 lb, or 45 kg); a pyridoxine
supplement was prescribed for 74 of these patients
(B-complex, pyridoxined and pyridoxine-48 series)
while the remaining 24 received only the other B-
group vitamins (pyridoxine-free series).
The mean B6 concentration on admission to
treatment for patients in this study was 1.00 µg/
100 ml of blood, the range including the middle
95 % of values being 0.50-1.83 µg/100 ml. Informa-
tion on B6 concentrations in healthy human subjects
is limited; Marsh, Greenberg & Rinehart (1955) have
reported a mean B6 concentration of 1.9 µg/100 ml
of blood in a small number of healthy American
adults. On these standards, the patients in this study
may be regarded as deficient in pyridoxine on
admission to treatment. (Supporting evidence for
this statement comes from the fact that in these
patients, despite treatment with high-dosage iso-
niazid, the concomitant administration of pyri-
doxine in as small a dosage as 6 mg resulted in a
substantial increase in whole blood GOT activity.)
In view of the observations made by Biehl &
Vilter (1954) and Short (1962) that the administra-
tion of isoniazid increases the excretion of B6, it was
rather surprising that, in the pyridoxine-free series,
the mean blood B6 concentration during treatment
(1.24 µg/100 ml) was significantly higher than the
pretreatment mean (1.00 µg/100 ml); this increase
was mainly due to the large mean obtained at
6 weeks (1.66 µg/100 ml). It is possible that the
latter was due to an increased intake of food (and
therefore, B6, in which the patients were probably
deficient), caused by an improvement in general con-
dition and increased appetite following the com-
mencement of effective chemotherapy. (Thus, 20 of
the 24 patients in this series gained weight in the
first month, the mean gain being 4.0 lb, or 1.8 kg.)
It could also have been due to the presence in blood
of considerable amounts of isonicotinoyl hydra-
zones of pyridoxal and its phosphate,1 a greater part
of which might have been formed in the tissues and
released into the blood-stream during the first weeks
of treatment. Lastly, it is possible that the increased
excretion of B6 reported by Biehl & Vilter (1954) and
1 When processing the blood samples prior to micro-
biological assay, these hydrazones are completely hydrolysed,
resulting in the liberation of the vitamin in equivalent amount.
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Short (1962) was caused by a depletion of the tissue
reserves of the vitamin without the blood concen-
trations being affected; this seems plausible since
greater amounts of vitamin B6 are contained in
tissues than in blood-for example, in the rat, the
tissues contain about 7-8 times, and in the rabbit
15-40 times, the concentration of pyridoxal phos-
phate circulating in blood (Boxer, Pruss & Goodhart,
1957; Wada et al., 1957; Wachstein & Moore,
1958).
The patients receiving a daily dose of 6 mg pyri-
doxine (B-complex and pyridoxined series) or
48 mg of pyridoxine (pyridoxine-48 series) showed
a marked elevation of the blood B6 concentrations
during treatment, confirming the observations of
Greenberg & Rinehart (1949) and Marsh, Greenberg
& Rinehart (1955). Thus, despite the continuation
of isoniazid in high dosage, the small dose of 6 mg
of pyridoxine a day increased the mean B6 con-
centration by over 2-fold and the larger daily dose of
48 mg by over 20-fold.
Considering next the whole-blood transaminase
values, the administration of the high-dosage
isoniazid resulted in a reduction of the GOT activity
in patients in the pyridoxine-free series, the reduc-
tion being 15 % (of the over-all pretreatment mean)
at 6 weeks, 27 % at 12 weeks, 19 % at 24 weeks and
12% at 52 weeks. The magnitude of the reduction
was smaller than that reported by Sass & Murphy
(1958; 31 % in 6 patients receiving 500 mg of iso-
niazid per day for 5 to 11 weeks) and by Bonstein
et al. (1961; 49% in 6 patients receiving 600 mg of
isoniazid for 13 weeks). In patients who received a
pyridoxine supplement, the mean GOT activity in-
creased significantly during treatmerit. Thus, the
concomitant administration of as small a dose of
pyridoxine as 6 mg had more than offset the inhibi-
tory effect of the high-dosage isoniazid, there being
an increase in mean GOT activity of the order
of 20 %. The corresponding increase was 38 % when
48 mg of pyridoxine were administered daily, as
compared with about 60% reported by Sass &
Murphy (1958), who had prescribed 25 mg of pyri-
doxine with 500 mg of isoniazid, and by Bonstein
et al. (1961), who had prescribed 30 mg of pyridoxine
hydrochloride with 600 mg of isoniazid.
As regards the influence of the rate of inactivation
of isoniazid on the whole-blood GOT activity, there
was no association between these two characteristics
on admission to treatment. However, during treat-
ment, slow inactivators in the pyridoxine-free,
B-complex and pyridoxine-6 series had, on the
average, a lower GOT than the corresponding rapid
inactivators (P ~ 0.01). Further, in the pyridoxine-
free series, 6 of 16 slow inactivators developed peri-
pheral neuropathy as compared with 1 of 8 rapid
inactivators, the development of the neuropathy
being associated with a substantial reduction in the
GOT activity. Of the 7 patients who developed the
neuropathy, 3 (including 1 of the 2 referred below)
continued to receive the high-dosage isoniazid but
were prescribed, in addition, pyridoxine (6 mg or
48 mg) daily; all 3 showed increases in B6 concentra-
tion and GOT activity.
No convulsions occurred in any of the patients
receiving a pyridoxine supplement. In contrast,
2 patients in the pyridoxine-free series (both of whom
developed peripheral neuropathy) had convulsions,
which did not recur after pyridoxine was given; one
of these had continued on the high-dosage isoniazid,
while the other was prescribed 400 mg of isoniazid.
This suggests that the convulsions were due to
impaired pyridoxine function, probably in a very
severe form, as the GOT activities in these 2 patients
at about the time of the convulsions were 145 and
105 units, the latter value being the lowest encoun-
tered in this study. Administration of isoniazid and
other hydrazides to experimental animals is known
to produce convulsions, which are associated with
low levels of g -aminobutyric acid in the brain, and
decreased activity of glutamate decarboxylase, a
pyridoxal-phosphate-requiring enzyme, which is
specific to the central nervous system and is involved
in the production of g -aminobutyric acid (Tower,
1956; Killam, 1958; Roberts, Baxter & Eidelberg,
1959; Roberts, 1960).
The findings in the present paper have shown that,
in patients receiving high-dosage isoniazid daily, (1)
the concomitant administration of a small daily sup-
plement of pyridoxine 6 mg brought about an
increase in the whole-blood GOT activity and B6
concentrations and prevented peripheral neuro-
pathy; (2) a B-complex preparation without pyri-
doxine failed to prevent a significant reduction in
GOT activity and the neuropathy ; (3) peripheral
neuropathy occurred predominantly among slow
inactivators, and those developing the neuropathy
had lower B6 concentrations and lower GOT activity
at the time than those who did not; and (4) the admi-
nistration of pyridoxine to patients with peripheral
neuropathy resulted in increased whole-blood GOT
activity and B6 concentrations. It may therefore be
concluded that there is a definite association be-
tween the signs and symptoms of isoniazid-induced
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peripheral neuropathy and diminished pyridoxine
function.
Investigations designed to determine whether the
reduction in whole-blood GOT activity observed in
the pyridoxine-free series was due to an insufficiency
of the coenzyme, pyridoxal phosphate (PLP), have
resulted in some interesting conclusions. Thus, pre-
incubation of blood samples with PLP brought
about a near doubling of the GOT activity in the
pyridoxine-free series; even so, the GOT activity was
less than that observed, without preincubation with
PLP, in the three series receiving a pyridoxine sup-
plement. This suggests that the lower GOT activity
in the pyridoxine-free series was due to a depletion
of both the coenzyme and the apoenzyme. Similar
observations have been made by Bergeret, Chatagner
& Fromageot (1955) and Hope (1955), who showed
that, in pyridoxine-deficient animals, liver cysteine-
sulfinate decarboxylase activity was completely
lost and no activity could be recovered even after
addition of PLP to the assay system, thus suggesting
loss of both the coenzyme and the apoenzyme.
The interesting finding in the present investigation
is not so much the loss of some of the apoenzyme as
the recovery of the enzyme activity after preincuba-
tion with PLP.
Another point of interest is that, even in patients
who were receiving 48 mg of pyridoxine daily and
who had high concentrations of B6 circulating in the
blood, the whole-blood GOT activity was increased
by 20% following preincubation with PLP. This
suggests that part of the B6 is present, not as the
coenzyme in the active form of pyridoxal phosphate
but as the precursors pyridoxine and pyridoxal, and
that this results in a relative deficiency of the co-
enzyme followed by inadequate saturation of the
apoenzyme. This lack of conversion of pyridoxine
and pyridoxal to pyridoxal phosphate might be
attributed to the partial inhibition of pyridoxal
kinase by high concentrations of isoniazid, since
McCormick & Snell(1959) have shown that isoniazid
is a potent inhibitor of this enzyme. It is therefore
likely that interference of isoniazid with the utiliza-
tion of B6 in the body might be a contributory factor
in producing an acute B6 deficiency with overt
clinical manifestations.
It was concluded earlier, from the clinical findings
of this double-blind study, that as small a daily dose
as 6 mg of pyridoxine could prevent peripheral neuro-
pathy and probably convulsions in patients receiving
a high dosage of isoniazid–namely, 12.5-15.6 mg/kg
body-weight (Tuberculosis Chemotherapy Centre,
Madras, 1963). This conclusion is now amply
strengthened by the findings of biochemical investi-
gations undertaken at the same time. These have
shown that both peripheral neuropathy and convul-
sions were associated with marked reduction in
whole-blood GOT activity, and that the concomitant
administration of 6 mg of pyridoxine with the high-
dosage isoniazid resulted in a significant increase in
GOT activity.
SUMMARY
1. Routine determinations of B6 concentration
and GOT activity in whole blood were undertaken
on admission to treatment and at 6, 12, 24 and
52 weeks thereafter for each of 98 patients with pul-
monary tuberculosis, who were prescribed isoniazid
alone for 1 year, in a single dose of 12.5-15.6 mg/kg
body-weight.
2. Each patient received, in addition, one of four
randomly allocated supplements for 1 year:
(a) a vitamin-B-complex preparation in a daily
dosage of 60 mg of aneurine hydrochloride, 30 mg
of riboflavine, 300 mg of nicotinamide, 18 mg of
panthenol and 6 µg of cyanocobalamin, pre-
scribed as 3 tablets twice daily (pyridoxine-free
series, 24 patients),
(b) the above vitamin-B-complex preparation
plus 6 mg of pyridoxine, prescribed together as
3 tablets twice daily (B-complex series, 24 patients),
(c) pyridoxine by itself in a daily dosage of 6 mg,
prescribed as 3 tablets twice daily (pyridoxined
series, 26 patients), and
(d) pyridoxine by itself in a daily dosage of 48 mg,
prescribed as 3 tablets twice daily (pyridoxine-48
series, 24 patients).
3. The study was conducted on a double-blind
basis, neither the patients nor the clinicians or labo-
ratory staff being aware of the nature of the supple-
ments given or of any subsequent changes in them.
4. On admission to treatment, the mean B6 con-
centration for the patients was 1.00 µg/100 ml, the
95 % range being 0.50-1.83 µg/100 ml. Subsequently,
the means increased significantly in all four series, the
“ treatment mean ” being largest in the pyridoxine-48
series.
5. The mean GOT activity (in whole blood) on
admission was 504 units, the 95% range being
315-702 units. Subsequently, there was a significant
reduction (of about 20%) in mean GOT activity in
the pyridoxine-free series, and a significant increase
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in each of the other three series, patients in all of
which received at least 6 mg of pyridoxine daily: the
increase was largest in the pyridoxine-48 series.
6. The reduced GOT activity during treatment.
in the pyridoxine-free series was due both to defi-
ciency of the coenzyme (pyridoxal phosphate) and
the apoenzyme.
7. The increased GOT activity during treatment
in the three pyridoxine series was due to an increase
of the apoenzyme, which suggests that the patients
were pyridoxine-deficient on admission to treatment.
8. Even 48 mg of pyridoxine per day failed to
saturate fully the GOT apoenzyme with the co-
enzyme pyridoxal phosphate.
9. There was no association between the rate of
inactivation of isoniazid and blood B6 concentrations,
either on admission or during treatment, or whole-
blood GOT activity on admission. However, during
treatment with high-dosage isoniazid, the mean
GOT activity for the slow inactivators in the pyri-
doxine-free, B-complex and pyridoxine-6 series was
significantly lower than that for the rapid inactivators.
10. Peripheral neuropathy developed in 7 patients,
all in the pyridoxine-free series; it occurred more
frequently among slow inactivators of isoniazid (6
of 16) than among rapid inactivators (1 of 8), and
was associated with a substantial reduction in the
whole-blood GOT activity during treatment, but no
apparent change in blood B6 concentration.
11. Two patients with peripheral neuropathy and
one with the neuropathy and convulsions were con-
tinued on high-dosage isoniazid, but prescribed pyri-
doxine (6 mg or 48 mg) daily in addition; the con-
vulsions did not recur and all 3 patients showed
increases in B6 concentration and GOT activity.
12. These findings show that there is a definite
association between the occurrence of isoniazid-in-
duced toxicity and diminished pyridoxine function.
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Annex
STATISTICAL PROCEDURES
DISTRIBUTIONS OF GOT ACTIVITIES AND B6
CONCENTRATIONS
The distributions of GOT activities on admission
to treatment and during treatment, as well as that
of B6 concentrations on admission, were fairly sym-
metric. However, the distributions of the B6 concen-
trations during treatment were considerably skew to
the right, probably because the interval between the
ingestion of drugs and collection of blood samples
was not regulated. Therefore, the range including
the middle 95% of the observations (i.e., excluding
2.5% at each extreme) has been presented in the
text as a measure of the variation in B6 concentra-
tions, in preference to the customary standard
deviation. For uniformity, the same procedure has
been adopted in the case of GOT activities also.
ANALYSIS OF DATA
Standard analysis of variance techniques were
used to assess the statistical significance of various
effects. All the analyses were undertaken on untrans-
formed data since no simple transformation could
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be found to correct for the skewness observed (see
above).
COMPARISON BETWEEN THE FOUR SERIES ON
ADMISSION TO TREATMENT
Since the proportions of slow inactivators in the
four series were dissimilar, being relatively small in
the B-complex series,. and since this could affect the
comparison of mean B6 concentrations and mean
GOT activities between the four series, an analysis
of variance procedure suitable for designs with dis-
proportionate subclass numbers was adopted
(Snedecor, 1956). In brief, this consists in computing
a weighted average of the mean of the slow inac-
tivators and the mean of the rapid inactivators in
each series, and using it for comparison between the
series.
INCOMPLETE DATA
On admission to treatment
As mentioned earlier (pages 856 and 858) estimates
of B6 concentrations and GOT activities on admission
to treatment were not available for 22 and 19
patients, respectively. Therefore, when assessing the
effect of the supplements on the B6 concentrations
and GOT activities during treatment, it was not
possible to use each patient as his own control.
The data were analysed as for a completely ran-
domized design (instead of a randomized block
design), the mean on admission being based, for
the sake of increased precision, on all available
estimates in the four series.
During treatment
In the pyridoxine-free series, patients were
excluded from the analysis from the time of diag-
nosis of peripheral neuropathy, thus making the
data incomplete during treatment. Since the missing
observations are not “ random losses ” (see also
pages 859-860), no attempt has been made to esti-
mate the missing observations; the “treatment mean ”
was computed for each patient from all the available
estimates up to the time of diagnosis and the mean
of these treatment means employed to characterize
the series.
In the B-complex, pyridoxine-6 and pyridoxine-48
series, 4, 3 and 3 estimates of B6 concentrations and 3,
3 and 2 estimates of GOT activities were not avail-
able, either because the blood samples were not
collected or because the volume collected was
inadequate. These missing values have been esti-
mated using standard statistical techniques
and the estimates included when computing the
means.
COMPARISONS DURING TREATMENT
Within series
Four comparisons were undertaken within each
series. Three of these were between the “ over-all
pretreatment mean ”, the “ treatment mean ” and
the mean at 36 weeks (the fourth was between the
average of the treatment means for slow inactivators
and that for rapid inactivators). Both for B6 concen-
trations and for GOT activities, the variances were dis-
similar for the estimates on admission, those during
treatment and those at 36 weeks; consequently,
modified t-tests (Cochran & Cox, 1956) were used.
Between series
Owing to unequal variances in the different series,
the statistical significance of differences between the
four series in the “ treatment means ” was assessed
using the modified t-test.
La présente etude se situe dans le cadre des travaux
menés au Centre de Chimiothérapie antituberculeuse de
Madras, Inde, sur la prevention des effets toxiques succé-
dant à l’administration de doses élevées d’isoniazide.
Admis en vue d’un traitement pour tuberculose pul-
monaire, 98 malades ont fait l’objet à leur admission, puis
au bout de 6, 12, 24 et 52 semaines, des examens hémato-
logiques de routine suivants: dosage de la vitamine B6 et
evaluation de l’activité de la transaminase glutamique
oxaloacétique (TGO) du sang complet. Le traitement
prescrit pour une durée d’un an était une seule dose quo-
tidienne d’isoniazide à raison de 12,5 à 15,6 mg/kg de
poids corporel. Chaque malade a reçu, en outre, pendant
un an, l’un des quatre supplements suivants, choisi aléa-
toirement : a) preparation de complexe vitaminique B aux
doses quotidiennes suivantes: 60 mg de chlorhydrate
d’aneurine, 30 mg de riboflavine, 300 mg de nicotinamide,
18 mg de panthénol et 6 µg de cyanocobalamine; on l’a
administrée à raison de 3 comprimés deux fois par jour
(série « sans pyridoxine », 24 malades); b) preparation
a additionnée de 6 mg de pyridoxine, à raison de
3 comprimés deux fois par jour (série « complexe-B »,
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24 malades); c) pyridoxine: 6 mg par jour, administrée
en 3 comprimé deux fois par jour (série « pyridoxine-6 »,
26 malades); d) pyridoxine: 48 mg par jour, donnée à
raison de 3 comprimés deux fois par jour (série « pyrido-
xine-48 », 24 malades). L’étude a été faite par la méthode
du double anonymat, malades, médecins et personnel de
laboratoire ignorant la nature des supplements adminis-
trés et leur modification ultérieure, le cas échéant.
Au moment de l’admission, la concentration moyenne
de vitamine B6 dans le sang des malades était de 1,00
µg/100 ml avec un intervalle de confiance à 95% allant
de 0,50 à 1,83 µg/100 ml. Par la suite, les moyennes ont
sensiblement augmenté dans les quatre séries, la moyenne
de traitement étant maximale dans la série « pyri-
doxine-48 ».
L’activite moyenne de la TGO du sang complet était
de 504 unites au moment de l’admission, l’intervalle de
confiance à 95 % étant de 315-702 unites. Par la suite, on
a observé dans la série « sans pyridoxine » une importante
reduction de l’activité moyenne de la TGO (environ 20 %) ;
dans les trois séries dont tous les malades avaient reçu
au moins 6 mg de pyridoxine par jour, on a constaté au
contraire une augmentation importante. C’est dans la
série « pyridoxine-48 » que l’accroissement a été le plus
fort. La reduction de l’activité de la TGO pendant le trai-
tement des malades de la série « sans pyridoxine » était due
à une carence tant de la coenzyme (phosphate de pyri-
doxal) que de l’apoenzyme. L’augmentation de l’activité
de la TGO pendant le traitement des malades des trois
series « pyridoxine » était due à une augmentation de l’apo-
enzyme, ce qui porte à croire que les malades souffraient
d’une carence en pyridoxine au moment de leur admis-
sion. Même à la dose de 48 mg par jour, la pyridoxine n’a
pu saturer de coenzyme (phosphate de pyridoxal) l’apo-
enzyme de la TGO.
On n’a relevé aucune relation entre la vitesse d’inacti-
vation de l’isoniazide et la teneur du sang en vitamine B6
ni à l’admission ni pendant le traitement, ou l’activité de
la TGO du sang complet à l’admission. Toutefois, au
cours du traitement par des doses élevées d’isoniazide,
l’activité moyenne de la TGO chez les inactivateurs lents
des séries « sans pyridoxine », « complexe B » et « pyri-
doxine-6 » a été nettement plus faible que chez les inacti-
vateurs rapides.
Chez 7 malades, tous de la série « sans pyridoxine », est
apparue une neuropathie périphérique; elle a été plus fré-
quente chez les inactivateurs lents (6 sur 16) que chez les
inactivateurs rapides (1 sur 8) et était associée à une réduc-
tion substantielle de la TGO du sang complet, sans varia-
tion apparente de la concentration en vitamine B6 du sang.
Chez deux malades atteints de neuropathie périphérique
et chez un autre atteint de neuropathie et de convulsions,
on a poursuivi le traitement à l’isoniazide à forte dose
mais avec addition de pyridoxine à raison de 6 ou de 48
mg par jour. Les convulsions n’ont pas réapparu et on a
observe chez les trois malades une augmentation de la
concentration en vitamine B6 et de l’activité de la TGO.
Ces constatations montrent l’existence d’une relation
certaine entre les effets toxiques de l’isoniazide et la dimi-
nution de la fonction pyridoxinique.
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